Pacific Biosciences of California(US:PACB) ZACKSยท2024-09-13 23:18Company Overview - Pacific Biosciences of California (PACB) closed at $1.81, reflecting a +0.56% change from the previous trading day's close, outperforming the S&P 500's gain of 0.54% [1] - Over the past month, PACB shares have increased by 6.51%, surpassing the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% [2] Financial Performance Expectations - The upcoming financial results are anticipated to show an EPS of -$0.20, which represents a 25.93% increase compared to the same quarter last year. Revenue is expected to be $41.9 million, indicating a 24.77% decrease year-over-year [3] - For the entire year, the Zacks Consensus Estimates forecast an EPS of -$0.95 and revenue of $168.07 million, reflecting changes of +14.41% and -16.18% respectively compared to the previous year [4] Analyst Estimates and Market Sentiment - Recent changes to analyst estimates for PACB suggest a shifting business landscape, with positive revisions indicating optimism about the company's outlook [5] - The Zacks Rank system, which correlates estimate revisions with share price momentum, currently ranks PACB as 3 (Hold), with a 9.17% decrease in the consensus EPS estimate over the last 30 days [6][7] Industry Context - The Medical - Instruments industry, which includes PACB, holds a Zacks Industry Rank of 63, placing it in the top 25% of over 250 industries. This ranking indicates that top-rated industries tend to outperform lower-rated ones by a factor of 2 to 1 [8]